Clinical Applications of PARP Inhibitors in Breast, Ovarian, and Prostate Cancer: Current Insights and Future Directions

Abstract: Poly(ADP-ribose) polymerase (PARP) inhibitors have emerged as an important therapeutic option for patients with homologous recombination repair (HRR)–deficient cancers, especially those with BRCA1/2 mutations. Since […]

Hemophagocytic Lymphohistiocytosis: New Grading Classification and Targeted Therapies

Abstract: Hemophagocytic lymphohistiocytosis (HLH), both primary/familial HLH and secondary HLH, is associated with multiorgan dysfunction caused by excessive immune activation and cytokine release. The high morbidity […]

Is There an Optimal Sequential Order to Androgen Receptor Axis Therapeutics?

Abstract: The hormonal therapeutic landscape in prostate cancer has expanded greatly over the last few decades with the advent of abiraterone acetate and second-generation antiandrogens such […]

Multikinase Inhibitors in Refractory Metastatic Colorectal Cancer: An Optimal Sequence?

Abstract: Despite major advances in management strategies, metastatic colorectal cancer remains an important clinical challenge because most patients experience progression after standard first- and second-line treatments. […]

The Clinical Applications of Next-Generation Sequencing and ctDNA/cfDNA in Lymphoma

Abstract: Next-generation sequencing (NGS) technology plays a pivotal role in understanding the molecular landscape in oncology by providing a comprehensive analysis of genomic mutations. The detection […]

What Cancer Patients May or May Not Be Surprised to Know About Survivorship

Abstract: The number of US cancer survivors has increased from fewer than 4 million in the 1970s to 18.1 million in 2022, with the increase reflecting […]

Unlocking the Potential of Patient-Reported Outcomes: Practical Uses in Routine Oncology Care

Abstract: A growing body of evidence supports the use of remote symptom monitoring based on patient-reported outcomes (PROs) to manage symptoms, improve quality of life, and […]

Converging Approaches in the Frontline Treatment of Mantle Cell Lymphoma

Abstract: Mantle cell lymphoma is a biologically and clinically heterogeneous subtype of non-Hodgkin lymphoma that affects predominantly older patients. The disease remains incurable with modern therapies. […]

Cancer and Cardiovascular Health: A Multidisciplinary Approach

Abstract: Early detection and improved cancer therapies have led to increases in cancer survivorship. There were 18.1 million cancer survivors in the United States alone in […]

Targeted Immunotherapy in the Treatment of Childhood and Adolescent Mature B-Cell Lymphoma

Abstract: Mature B-cell non-Hodgkin lymphomas (B-NHLs) comprise approximately 40% to 60% of all NHLs among children, adolescents, and young adults. Although overall survival with mature B-NHL […]

Integration of Immunotherapy Into the Frontline Treatment of Acute Lymphoblastic Leukemia

Abstract: Immunotherapy has transformed the treatment of acute lymphoblastic leukemia (ALL) over the past 2 decades, leading to excellent outcomes in adults and children. This is […]

First-line Use of Antiangiogenic Agents in Unresectable Hepatocellular Carcinoma: A Double-Edged Sword?

Abstract: Treatment options for hepatocellular carcinoma (HCC), the most prevalent primary liver malignancy, have historically been limited, particularly in unresectable cases with underlying cirrhosis. Initial systemic […]

Revolutionizing Breast Cancer Treatment: The Promise of Antibody-Drug Conjugates

Abstract: Antibody-drug conjugates (ADCs) have significantly advanced the treatment of breast cancer by integrating the specificity of monoclonal antibodies with the cytotoxic efficacy of chemotherapy, thereby […]

Non–Clear Cell Renal Cell Carcinoma: Unpacking a Messy Term

Abstract: Non–clear cell renal cell carcinoma (nccRCC) is a heterogeneous category comprising approximately 25% of epithelial renal tumors. Unlike their far more common clear cell counterpart, […]

Genetics of Prostate Cancer

Abstract: Prostate cancer is a highly heritable cancer, with contributions from rare pathogenic variants in prostate cancer predisposition genes (eg, HOXB13, BRCA2) and from common genetic […]

Update on PARP Inhibitors for the Treatment of Ovarian Cancer

Abstract: Poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors (PARPis) were first granted US Food and Drug Administration (FDA) approval for ovarian cancer. Trials have focused on high-grade serous […]

Targeting RAS in Gastrointestinal Malignancies

Abstract: Kirsten rat sarcoma virus (KRAS) is one of the prevalent oncogenic drivers in gastrointestinal (GI) cancers, including pancreatic ductal adenocarcinoma and colorectal cancer. The KRAS […]

Management of Oligoprogressive and Oligopersistent Disease in Advanced NSCLC

Abstract: The oligometastatic disease state is defined as an intermediate state between localized cancer and widespread systemic metastases. Oligoprogression is defined as a subgroup in which […]

Personalized Approaches to Breast Radiotherapy: Strategies for Treatment Refinement

Abstract: Radiotherapy (RT) is a crucial component of the adjuvant treatment of breast cancer that often follows breast conservation or mastectomy to further reduce the risk […]

Targeted Immunotherapy in the Treatment of Childhood and Adolescent Classic Hodgkin Lymphoma

Abstract: Childhood and adolescent classic Hodgkin Lymphoma (cHL) has long been a model for how we balance improved outcomes with increased toxicities in pediatric cancer. The […]